Daptomycin


Thông tin kê toa tóm tắt
Chỉ định/Công dụng
Listed in Dosage.
Liều dùng/Hướng dẫn sử dụng
Adult : IV Complicated skin and skin structure infections 4 mg/kg/day infused over 30 min for 7-14 days. Staphylococcus aureus bacteraemia 6 mg/kg/day infused over 30 min for 2-6 wk.
Dosage Details
Intravenous
Complicated skin and skin structure infections
Adult: 4 mg/kg once daily for 7-14 days, by infusion over 30 min or by inj over 2 min.

Intravenous
Staphylococcus aureus bacteraemia
Adult: 6 mg/kg once daily for 2-6 wk, by infusion over 30 min.
Renal Impairment
Complicated skin and skin structure infections:
Patients on haemodialysis or CAPD: 4 mg/kg once every 48 hr.
CrCl Dosage
<30 4 mg/kg once every 48 hr.
Staphylococcus aureus Bacteraemia:
Patients on haemodialysis or CAPD: 6 mg/kg once every 48 hr.
CrCl Dosage
<30 6 mg/kg once every 48 hr.
Hướng dẫn pha thuốc
Reconstitute w/ 10 mL of NaCl 0.9% inj using aseptic technique. Gently rotate the vial to wet the powd and allow it to stand for 10 min. To obtain a completely reconstituted soln, gently swirl or rotate the vial. Do not shake/agitate vial during and after reconstitution. Further dilute the reconstituted soln w/ NaCl 0.9% inj for IV infusion. The final concentration should not exceed 20 mg/mL.
Tương kỵ
Dextrose-containing soln, ceftriaxone.
Chống chỉ định
Hypersensitivity.
Thận trọng
Renal impairment. Patient w/ persisting or relapsing Staphylococcus aureus infection. Pregnancy and lactation.
Phản ứng phụ
Diarrhoea, vomiting, constipation, nausea, dyspepsia, loose stools, and abdominal pain; pain in extremity, myositis, myopathy, back pain,; headache, dizziness, insomnia, anxiety, pharyngolaryngeal pain, pleural effusion; UTI, osteomyelitis, sepsis, bacteraemia, peripheral oedema, pyrexia, chest pain, asthenia, rash, pruritus, erythema, increased sweating, CK elevations, HTN, hyperkalaemia, hypokalaemia, anaemia, hypotension, angioedema, drug rash w/ eosinophilia and systemic symptoms (DRESS). Rarely, jaundice, infusion reactions, rhabdomyolysis, peripheral neuropathy.
Potentially Fatal: Anaphylaxis/hypersensitivity reactions, eosinophilic pneumonia, superinfection including Clostridium difficile-associated diarrhoea and colitis.
IV/Parenteral: B
MonitoringParameters
Closely monitor for signs and symptoms of eosinophilic pneumonia (e.g. new onset or worsening fever, dyspnoea). Serum creatine kinase should be monitored at least wkly during therapy.
Tương tác
Enhanced adverse/toxic effects w/ HMG-CoA reductase inhibitors (e.g. simvastatin). NSAIDs (e.g. diclofenac, ibuprofen) may reduce excretion of daptomycin and increase risk of renal impairment. Synergistic antibacterial effects against staphylococci and enterococci w/ aminoglycosides (e.g. gentamicin, tobramycin), rifampicin or β-lactam anti-infectives (e.g. penicillins, cephalosporins).
Lab Interference
False prolongation of prothrombin time (PT) and elevation of INR if certain recombinant thromboplastin reagents are used for these tests.
Tác dụng
Description: Daptomycin is a cyclic lipopeptide antibacterial derived from the fermentation of Streptomyces roseosporus. It causes bacterial cell death by binding to bacterial membranes and disrupting the membrane potential; thus inhibiting the synthesis of protein, DNA and RNA. Daptomycin exhibits rapid concentration-dependent bactericidal effects against susceptible gm+ve bacteria in vitro.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: 0.5-0.8 hr (IV).
Distribution: Primarily distributed into extracellular space. Crosses the blood-brain barrier and placenta. Volume of distribution: 0.1 L/kg. Plasma protein binding: Approx 90% (mainly serum albumin).
Metabolism: Not metabolised by hepatic CYP450 isoenzymes.
Excretion: Via urine (78%, primarily as unchanged drug) and faeces (6%). Elimination half-life: Approx 8 hr.
Bảo quản
Store between 2-8°C. Reconstituted soln: Stable for 12 hr when stored at 25°C and 24 hr between 2-8°C.
Phân loại MIMS
Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Daptomycin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2020 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Cubicin
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in